NO309266B1 - Fremgangsmåte for fremstilling av optisk anriket bupivacain - Google Patents

Fremgangsmåte for fremstilling av optisk anriket bupivacain Download PDF

Info

Publication number
NO309266B1
NO309266B1 NO971903A NO971903A NO309266B1 NO 309266 B1 NO309266 B1 NO 309266B1 NO 971903 A NO971903 A NO 971903A NO 971903 A NO971903 A NO 971903A NO 309266 B1 NO309266 B1 NO 309266B1
Authority
NO
Norway
Prior art keywords
solvent
bupivacaine
water
levobupivacaine
optically enriched
Prior art date
Application number
NO971903A
Other languages
English (en)
Norwegian (no)
Other versions
NO971903L (no
NO971903D0 (no
Inventor
Marianne Langston
Benjamin Mark Skead
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9421476A external-priority patent/GB9421476D0/en
Priority claimed from GBGB9504926.8A external-priority patent/GB9504926D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of NO971903L publication Critical patent/NO971903L/no
Publication of NO971903D0 publication Critical patent/NO971903D0/no
Publication of NO309266B1 publication Critical patent/NO309266B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO971903A 1994-10-25 1997-04-24 Fremgangsmåte for fremstilling av optisk anriket bupivacain NO309266B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9421476A GB9421476D0 (en) 1994-10-25 1994-10-25 Process and salt
GBGB9504926.8A GB9504926D0 (en) 1995-03-10 1995-03-10 Crystallisation
PCT/GB1995/002513 WO1996012699A1 (fr) 1994-10-25 1995-10-23 Cristallisation de la levobupicavaine et des analogues de celle-ci

Publications (3)

Publication Number Publication Date
NO971903L NO971903L (no) 1997-04-24
NO971903D0 NO971903D0 (no) 1997-04-24
NO309266B1 true NO309266B1 (no) 2001-01-08

Family

ID=26305863

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971903A NO309266B1 (no) 1994-10-25 1997-04-24 Fremgangsmåte for fremstilling av optisk anriket bupivacain

Country Status (16)

Country Link
US (1) US5994548A (fr)
EP (1) EP0788480B1 (fr)
JP (1) JP3911545B2 (fr)
AT (1) ATE245629T1 (fr)
AU (1) AU698637B2 (fr)
CA (1) CA2200355C (fr)
DE (1) DE69531356T2 (fr)
DK (1) DK0788480T3 (fr)
ES (1) ES2202375T3 (fr)
FI (1) FI117438B (fr)
HU (1) HU227420B1 (fr)
MX (1) MX9703024A (fr)
NO (1) NO309266B1 (fr)
PL (1) PL183210B1 (fr)
PT (1) PT788480E (fr)
WO (1) WO1996012699A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0002246A (pt) 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
BRPI0104491B8 (pt) * 2001-10-10 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda n-(2,6-dimetilfenil)-1-propil-2-piperidinocarboxamida; processo de obtenção dos enantiômeros; mistura não racêmica dos anantiômeros e seu processo de obtenção e composição farmacêutica.
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP2959893A1 (fr) 2002-12-13 2015-12-30 DURECT Corporation Système d'administration de médicament par voie orale comprenant des matériaux de support liquides à viscosité élevée
US7094812B2 (en) * 2003-04-24 2006-08-22 Xerox Corporations Colorant compositions
US6790267B1 (en) * 2003-04-24 2004-09-14 Xerox Corporation Colorant compositions
PL1809329T3 (pl) 2004-09-17 2012-08-31 Durect Corp Kompozycja znieczulająca zawierająca saib o przedłużonym uwalnianiu do stosowania miejscowego
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP2009535327A (ja) * 2006-04-25 2009-10-01 ディシュマン・ファーマシューティカルズ・アンド・ケミカルズ・リミテッド ロピバカイン塩酸塩無水物およびその調製
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
WO2009088414A2 (fr) 2007-12-06 2009-07-16 Durect Corporation Formes posologiques pharmaceutiques orales
ES2383714T3 (es) * 2008-01-15 2012-06-25 Pharmathen S.A. Proceso para preparar un compuesto (S)-1-alquil-2',6'-pipecoloxilidídico
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN103073484B (zh) * 2013-01-28 2014-10-22 山东诚创医药技术开发有限公司 一种甲哌卡因及其光学对映体的制备方法
CA2905131A1 (fr) 2013-03-15 2014-09-18 Durect Corporation Compositions ayant un agent de modification rheologique pour reduire une variabilite de dissolution
IL290150B2 (en) * 2016-12-26 2024-03-01 Cellix Bio Private Ltd Compounds and methods for treating chronic pain
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE341404B (fr) * 1967-05-18 1971-12-27 Sterling Drug Inc
US4695576A (en) * 1984-07-09 1987-09-22 Astra Lake Medel Aktiebolag L-N-n-propylpipecolic acid-2,6-xylidide

Also Published As

Publication number Publication date
DE69531356D1 (de) 2003-08-28
NO971903L (no) 1997-04-24
FI971711A0 (fi) 1997-04-22
PL183210B1 (pl) 2002-06-28
DE69531356T2 (de) 2004-05-27
CA2200355A1 (fr) 1996-05-02
DK0788480T3 (da) 2003-09-29
HU227420B1 (en) 2011-05-30
AU698637B2 (en) 1998-11-05
MX9703024A (es) 1997-10-31
FI971711A (fi) 1997-04-22
PL319829A1 (en) 1997-09-01
JP3911545B2 (ja) 2007-05-09
ATE245629T1 (de) 2003-08-15
NO971903D0 (no) 1997-04-24
HUT77631A (hu) 1998-06-29
FI117438B (fi) 2006-10-13
EP0788480B1 (fr) 2003-07-23
JPH10507464A (ja) 1998-07-21
PT788480E (pt) 2003-12-31
US5994548A (en) 1999-11-30
WO1996012699A1 (fr) 1996-05-02
CA2200355C (fr) 2007-03-06
AU3704895A (en) 1996-05-15
EP0788480A1 (fr) 1997-08-13
ES2202375T3 (es) 2004-04-01

Similar Documents

Publication Publication Date Title
NO309266B1 (no) Fremgangsmåte for fremstilling av optisk anriket bupivacain
WO2007038277A2 (fr) Resolution de derives d'acide alpha-(phenoxy) phenylacetique avec des naphtyl-alkylamines
AU696875B2 (en) New process for the preparation of ropivacaine hydrochloride monohydrate
AU2001278094B2 (en) Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperindinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride
JP2011012032A (ja) 光学活性な3−アミノピペリジンの製造方法および製造の中間体
DK152752B (da) Fremgangsmaade til fremstilling af l-sulpirid
US7897777B2 (en) Process of enantiomeric resolution of D,L-(±)-threo-methylphenidate
KR100472609B1 (ko) 레보부피바카인과그의유사체의결정화벙법
CN111302996A (zh) 一种高手性纯度的富马酸氯马斯汀的制备方法
US20200131126A1 (en) Process for the Separation of Optical Isomers of Racemic 3-Alkylpiperidine-Carboxylic Acid Ethyl Esters
JP4000113B2 (ja) (3s)−3−メトキシカルボニル−4−フェニル酪酸金属塩およびその使用方法
WO2002068391A1 (fr) Procede de dissolution de melanges racemiques de derives de piperidine
WO2021166934A1 (fr) Procédé de fabrication de composé pyrrolidine
US20040039206A1 (en) Process for resolving racemic mixtures of piperidine derivatives
CN117510398A (zh) 一种高光学纯度(3r,4r)/(3s,4s)-n-boc-4-氨基-3-羟基哌啶的制备方法
WO2010079605A1 (fr) Procédé de production de la 1-benzyl-3-aminopyrrolidine de pureté élevée
EP1178962A1 (fr) Procede de preparation d'acetate de paroxetine et de ses analogues
JPH0940621A (ja) 光学活性インダニルメチルアミン誘導体及びその製造法
WO2000039121A1 (fr) Procede de preparation d'un acetate de paroxetine ou d'analogues de paroxetine
JPH0687828A (ja) 環化反応を用いるジフルオロメチル化合物の合成
EP1140912A1 (fr) Procede de preparation d'un sel d'acetate de paroxetine ou d'analogues de paroxetine

Legal Events

Date Code Title Description
MK1K Patent expired